SYNTHESIS AND CHARACTERIZATION OF A POLYVALENT ESCHERICHIA-COLI O-POLYSACCHARIDE TOXIN-A CONJUGATE VACCINE

被引:24
作者
CRYZ, SJ [1 ]
QUE, JO [1 ]
CROSS, AS [1 ]
FURER, E [1 ]
机构
[1] WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, WASHINGTON, DC 20307 USA
关键词
VACCINE; ESCHERICHIA COLI; CONJUGATES;
D O I
10.1016/0264-410X(94)00009-C
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A 12-valent Escherichia coli O-polysaccharide (O-PS)-toxin A conjugate vaccine was formulated Nonpyrogenic, low-molecular-weight O-PS, was derived from lipopolysaccharides (LPS) of the following serotypes: 01, 02, 04, 06, 07, 08, 012 015, 016, 018, 025, and 075. Individual O-PS were covalently coupled to Pseudomonas aeruginosa toxin A using adipic acid dihydrazide as a spacer molecule and carbodiimide as a coupling agent. On a weight basis, the final multivalent vaccine was composed of 43% O-PS and 57% toxin A. The vaccine was nontoxic and nonpyrogenic in standard animal tests. Immunization of rabbits engendered a marked rise (6-74-fold) in anti-LPS immunoglobulin G (IgG) antibody titers. When passively transferred to mice, immune turze rabbit IgG conferred statistically significant (p<0.05) protection against a challenge with 9 of the 12 vaccine serotypes. For two serotypes, although the mortality rate declined by greater than or equal to 50% in the passively immunized versus the control group, the difference did not reach statistical significance. The degree of protection provided by passively transferred IgG was influenced by both the anti-LPS antibody levels in the IgG preparation and the virulence of the challenge strain. Active immunization of mice with either conjugate vaccine or killed E. coli, whole cells did not confer protection. This was most probably due to the fact that these antigens induced a meagre anti-LPS IgG antibody response.
引用
收藏
页码:449 / 453
页数:5
相关论文
共 24 条
[1]   NOSOCOMIAL INFECTION - THE IRREDUCIBLE MINIMUM [J].
AYLIFFE, GAJ .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1986, 7 (02) :92-95
[2]   IMMUNOLOGICAL CHARACTERIZATION OF ANTIBODY-RESPONSES TO ESCHERICHIA-COLI O-ANTIGENS IN BACTEREMIC PATIENTS [J].
BRAUNER, A ;
SVENSON, SB ;
WRETLIND, B .
SERODIAGNOSIS AND IMMUNOTHERAPY IN INFECTIOUS DISEASE, 1988, 2 (04) :291-299
[3]  
BRYAN CS, 1983, REV INFECT DIS, V5, P629
[4]   THE IMPORTANCE OF THE K1 CAPSULE IN INVASIVE INFECTIONS CAUSED BY ESCHERICHIA-COLI [J].
CROSS, AS ;
GEMSKI, P ;
SADOFF, JC ;
ORSKOV, F ;
ORSKOV, I .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (02) :184-193
[5]   THE HUMAN-ANTIBODY RESPONSE DURING NATURAL BACTEREMIC INFECTION WITH GRAM-NEGATIVE BACILLI AGAINST LIPOPOLYSACCHARIDE CORE DETERMINANTS [J].
CROSS, AS ;
SIDBERRY, H ;
SADOFF, JC .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (02) :225-236
[6]   PROTECTION AGAINST PSEUDOMONAS-AERUGINOSA INFECTION IN A MURINE BURN WOUND SEPSIS MODEL BY PASSIVE TRANSFER OF ANTITOXIN-A, ANTIELASTASE, AND ANTILIPOPOLYSACCHARIDE [J].
CRYZ, SJ ;
FURER, E ;
GERMANIER, R .
INFECTION AND IMMUNITY, 1983, 39 (03) :1072-1079
[7]   PRODUCTION AND CHARACTERIZATION OF A HUMAN HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN AGAINST PSEUDOMONAS-AERUGINOSA AND KLEBSIELLA SPECIES [J].
CRYZ, SJ ;
FURER, E ;
SADOFF, JC ;
FREDEKING, T ;
QUE, JU ;
CROSS, AS .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (05) :1055-1061
[8]   SYNTHESIS AND CHARACTERIZATION OF ESCHERICHIA-COLI O-18 O-POLYSACCHARIDE CONJUGATE VACCINES [J].
CRYZ, SJ ;
CROSS, AS ;
SADOFF, JC ;
FURER, E .
INFECTION AND IMMUNITY, 1990, 58 (02) :373-377
[9]   SAFETY AND IMMUNOGENICITY OF ESCHERICHIA-COLI O-18 O-SPECIFIC POLYSACCHARIDE (O-PS)-TOXIN-A AND O-PS-CHOLERA TOXIN CONJUGATE VACCINES IN HUMANS [J].
CRYZ, SJ ;
CROSS, AS ;
SADOFF, JC ;
WEGMANN, A ;
QUE, JU ;
FURER, E .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (05) :1040-1045
[10]   COLORIMETRIC METHOD FOR DETERMINATION OF SUGARS AND RELATED SUBSTANCES [J].
DUBOIS, M ;
GILLES, KA ;
HAMILTON, JK ;
REBERS, PA ;
SMITH, F .
ANALYTICAL CHEMISTRY, 1956, 28 (03) :350-356